washington u.s. senate republican leader mitch mcconnell tell reuters wednesday expect bipartisan support approval bill authorize taxpayer industry fund u.s. food drug administration bill reauthorize prescription drug user fee act would let fda continue collect hundreds millions dollars drugmakers medical device company partially cover cost review new products u.s. taxpayers fund remainder extremely important bill think able move bipartisan basis mcconnell say interview l1n1iq1ch fda charge company review products since 1992. tuesday president donald trump propose 2018 budget industry pay full cost drug medical device review industry present pay 60 percent proposal unlikely approve cycle reauthorization user fee bill typically negotiate fda industry period several years early month bill approve senate panel 21-2 vote must renegotiate every five years fda review drug approval rejection many company include major ones pfizer inc merck co inc johnson johnson pharmaceutical company base overseas include roche hold ag novartis ag also pay fee u.s.-approved drug exclusive mcconnell expect bipartisan support bill reauthorizing fda user fee